Additional data: Adrie et al.
|
Baseline after Solvent |
NO 1 ppm |
NO 5 ppm |
NO 10 ppm |
NO 20 ppm |
PaO2 (mmHg) |
66 ± 11 |
85 ± 14* |
99 ± 20** |
125 ± 22** |
102 ± 26** |
QVA/QT (%) |
49.4 ± 2.1 |
45 ± 2.2 |
41.2 ± 3.9* |
39.5 ± 3.3** |
42.2 ± 3** |
LAP (mmHg) |
10 ± 1 |
10 ± 1 |
10 ± 1 |
10 ± 1 |
10 ± 1 |
CVP (mmHg) |
9 ± 1 |
10 ± 1 |
10 ± 1 |
10 ± 1 |
9 ± 1 |
PAP (mmHg) |
24 ± 1 |
23 ± 1* |
20 ± 1** |
20 ± 1* |
22 ± 1 |
PVR (dynes·sec·cm-5) |
384 ± 56 |
325 ± 60 |
250 ± 51* |
276 ± 62* |
320 ± 47 |
SAP (mmHg) |
85 ± 10 |
85 ± 8.7 |
86 ± 12 |
86 ± 9 |
82 ± 12 |
SVR (dynes·sec·cm-5) |
2111 ± 312 |
1989 ± 272 |
2168 ± 446 |
2160 ± 273 |
2160 ± 352 |
CO (l·min-1) |
2.9 ± 0.2 |
3.2 ± 0.1 |
3.2 ± 0.3 |
2.9 ± 0.1 |
2.9 ± 0.3 |
cGMP (pmol·ml-1) |
22.7 ± 1.8 |
30.5 ± 3.5 |
36.5 ± 2.7* |
46 ± 12** |
70 ± 22** |
Supplemental Table 1. Effect of inhaled NO during solvent infusion on hemodynamics and gas exchange. Second dose response trials after solvent administration (n=5). Absolute value of arterial blood gas tensions (PaO2), venous admixture (QVA/QT), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and cardiac output (CO). cGMP: arterial plasma guanosine 3’,5’-cyclic monophosphate (n=3). Nitric oxide doses were administered in random order. * p<0.05, ** p<0.01 vs baseline.
Additional data: Adrie et al.
|
Baseline after Zaprinast |
NO 1 ppm |
NO 5 ppm |
NO 10 ppm |
NO 20 ppm |
PaO2 (mmHg) |
70 ± 11 |
69 ± 16 |
67 ± 14 |
72 ± 12 |
71 ± 15 |
QVA/QT (%) |
42.2 ± 4.5 |
42 ± 2.6 |
40.5 ± 3.2 |
44.6 ± 3.2 |
43.1 ± 4 |
LAP (mmHg) |
10 ± 1 |
10 ± 1 |
10 ± 1 |
10 ± 1 |
10 ± 1 |
CVP (mmHg) |
10 ± 1 |
10 ± 1 |
10 ± 1 |
10 ± 1 |
11 ± 1 |
PAP (mmHg) |
19 ± 1 |
19 ± 1 |
19 ± 1 |
18 ± 1 |
19 ± 1 |
PVR (dynes·sec·cm-5) |
190 ± 27 |
199 ± 24 |
193 ± 31 |
171 ± 24 |
198 ± 32 |
SAP (mmHg) |
81 ± 3 |
78 ± 5 |
81 ± 5.5 |
85 ± 4 |
79 ± 6 |
SVR (dynes·sec·cm-5) |
1512 ± 144 |
1440 ± 141 |
1384 ± 144 |
1424 ± 129 |
1440 ± 216 |
CO (l·min-1) |
4 ± 0.2 |
3.9 ± 0.3 |
4.1 ± 0.4 |
4.4 ± 0.4 |
4.2 ± 0.5 |
cGMP (pmol·ml-1) |
42.1 ± 7.5 |
70.8 ± 6.7* |
81.4 ± 10.8** |
94.5 ± 8.5** |
104 ± 8.5** |
Supplemental Table 2. Effect of inhaled NO during Zaprinast infusion on hemo-dynamics and gas exchange. Second dose response trials after Zaprinast administration (n=10). Absolute value of arterial blood gas tensions (PaO2), venous admixture (QVA/QT), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), and cardiac output (CO). cGMP: arterial plasma guanosine 3’,5’-cyclic monophosphate (n=7). Nitric oxide doses were administered in random order. * p<0.05, ** p<0.01 vs baseline.